{"id":"W4376956449","doi":"10.3390/curroncol30050380","title":"The CADTH pCODR Expert Review Committee Process Explained. Comment on Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Canadian Agency for Drugs and Technologies in Health; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Pertuzumab; Medicine; Breast cancer; Dilemma; Cancer; Family medicine; Trastuzumab; Oncology; Internal medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":true,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02627717,0.00168499,0.003529987,0.002410419,0.01437408,0.008947971,0.00855674,0.083243,0.01995935],"category_scores_gemma":[0.133135,0.001999937,0.005076997,0.00289732,0.007739617,0.004222259,0.005035894,0.06903548,0.01518856],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.04270693,"about_ca_system_score_gemma":0.09124267,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.3462993,"about_ca_topic_score_gemma":0.5300143,"domain_scores_codex":[0.9714141,0.005136607,0.002632921,0.002766685,0.0133763,0.004673412],"domain_scores_gemma":[0.9168194,0.02335594,0.003975432,0.001705593,0.04591133,0.008232324],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00001154486,0.000001662824,0.00002892635,0.00003122484,0.000003600676,0.00004172997,0.00003167925,0.000005745452,0.0000128116,0.0002585067,0.9990873,0.0004851724],"study_design_scores_gemma":[0.00006929236,0.00001841378,0.0005767412,0.000577338,0.00003956633,0.0000988032,0.0002222078,0.0000592325,0.0001114948,0.0007482105,0.9974163,0.00006234193],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.00005924811,0.001314161,0.00006948546,0.959614,0.03631964,0.00005723529,0.0004136364,0.00004301862,0.002109602],"genre_scores_gemma":[0.0004449753,0.0006587761,0.00010336,0.9831125,0.008543408,0.0001227234,0.00009488516,0.00002916046,0.006890171],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.9572931,"threshold_uncertainty_score":0.6885672,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1288503951715565,"score_gpt":0.4987084503139557,"score_spread":0.3698580551423991,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}